Theratechnologies ROCE
What is the ROCE of Theratechnologies?
The ROCE of Theratechnologies Inc. is -197.87%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on NASDAQ compared to Theratechnologies
What does Theratechnologies do?
theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.
Companies with roce similar to Theratechnologies
- Reeds Inc has ROCE of -201.51%
- Intersect ENT Inc has ROCE of -200.74%
- Plurilock Security has ROCE of -199.71%
- Nimy Resources Ltd has ROCE of -199.29%
- Catheter Precision has ROCE of -199.22%
- T2 Biosystems has ROCE of -198.26%
- Theratechnologies has ROCE of -197.87%
- Tethyan Resource Corp has ROCE of -197.59%
- Pac Roots Cannabis has ROCE of -197.40%
- Acura Pharmaceuticals has ROCE of -196.81%
- Catasys has ROCE of -196.67%
- Odyssey Semiconductor Technologies has ROCE of -196.64%
- Nican has ROCE of -195.62%